Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma

Completed · Phase 2

Conditions studied: Melanoma

In brief

This Phase II study is designed to evaluate the anti-tumor activity of three dose groups of SB-485232 (0.01, 0.1, and 1.0 mg/kg/day) administered intravenously as a single agent in subjects with previously untreated metastatic melanoma.

Key facts

Study ID

NCT00107718

Run by

GlaxoSmithKline

People needed

64

Starts

2004-11-15

Expected to finish

2006-05-19

Last updated by the study team

2017-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have melanoma that has spread beyond the original location and has not yet been treated.
• Tissue from the spreading melanoma should have been tested to confirm it is melanoma.

You may not qualify if…

• Patients having hepatitis or HIV infection.
• Taking corticosteroids.
• Patients with the primary site being occular melanoma or patients with melanoma of the brain.

Where it is running

• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — San Francisco, California, United States
• GSK Investigational Site — Santa Monica, California, United States
• GSK Investigational Site — New Haven, Connecticut, United States
• GSK Investigational Site — Jacksonville, Florida, United States
• GSK Investigational Site — Miami Beach, Florida, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Indianapolis, Indiana, United States
• GSK Investigational Site — Lutherville-Timonium, Maryland, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Toledo, Ohio, United States
• GSK Investigational Site — Pittsburgh, Pennsylvania, United States
• GSK Investigational Site — Waratah, New South Wales, Australia
• GSK Investigational Site — Westmead, New South Wales, Australia
• GSK Investigational Site — Douglas, Queensland, Australia
• GSK Investigational Site — South Brisbane, Queensland, Australia
• GSK Investigational Site — Woolloongabba, Queensland, Australia
• GSK Investigational Site — Hobart, Tasmania, Australia
• GSK Investigational Site — East Melbourne, Victoria, Australia
• GSK Investigational Site — Nedlands, Western Australia, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.